AUSTIN, Texas, Feb. 14 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. announced today that a patent has been awarded by the U.S. Patent and Trademark Office which covers, for example, administration of chemotherapeutic drugs, radiation therapies, or other agents that have a damaging effect on the DNA of cancer cells, to a cancer patient, followed by administration of a desired therapeutic gene, such as one or more of Introgen’s molecular therapies. While useful for cancer treatments, the patent claims are not limited to oncology use and may have utility in other diseases. The patent, U.S. Patent No. 6,989,375, is one of numerous patents, pending or issued, that Introgen has licensed exclusively from the Board of Regents of The University of Texas System which cover its therapies.
This patent is based on the finding that the potency of any gene based product, including Introgen’s current product candidates, may be increased by pretreatment of cancer cells with chemotherapy or other DNA damaging agents. In particular Introgen has found that when cancer cells are pretreated with chemotherapy agents designed to cause DNA damage, followed by administration of a vector encoding a tumor suppressor gene, such as ADVEXIN or INGN 241, the result is an increase in expression of the selected tumor suppressor gene. This effect is observed in cancer cells when the selected chemotherapy is designed to damage DNA.
Virtually all cancer patients receive DNA damaging agents such as chemotherapy or radiotherapy as part of a standard treatment regimen. By treating cancer cells with chemotherapy and/or radiotherapy prior to receiving targeted molecular therapies, the effects of the treatment are enhanced. This enhanced therapeutic effect is not dependent on the type of cancer or the method by which a patient receives chemotherapy or radiotherapy.
“Because this patent is applicable to any gene based therapy and not limited to Introgen’s proprietary pipeline, it further solidifies and expands Introgen’s leading position with its own combination therapy. Thus, this is an important patent to any company interested in commercially pursuing such combination therapies,” said David L. Parker, J.D., Ph.D., vice president of Intellectual Property for Introgen. “This patent further validates Introgen’s intellectual property strategy, which is to patent technology that is clinically useful, can be broadly applied to a variety of products and predicts new, less toxic ways to treat cancer, particularly in therapies that may lessen the side effects of currently available treatments.”
Introgen holds a licensing agreement with M. D. Anderson to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. The University of Texas Board of Regents owns stock in Introgen. These arrangements are managed in accordance with M.D. Anderson’s conflict of interest policies.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Statements in this release that are not strictly historical may be “forward-looking” statements, including but are not limited to those relating to Introgen’s intellectual property portfolio. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen’s operations and business environment, including Introgen’s stage of product development and the limited experience in the development of gene- based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, Introgen’s patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website at: http://www.introgen.com .
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: c.burke@introgen.com
Introgen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc.,+1-512-708-9310, ext. 322, or c.burke@introgen.com
Web site: http://www.introgen.com/
